Grant: CIHR Fellowship
Direct Payment
$150,000.00
Improving the immune response to spinal cord injury using galectin-1
EF 2010-11
Résumé
The earliest documented cases of spinal cord injury (SCI) are in ancient Egyptian texts. 2500 years later, we are beginning to understand events that prevent repair after SCI. SCI permanently disconnects nerve cells (neurons) from other neurons in the spinal cord. Invading immune cells called macrophages worsen the situation by releasing toxic chemicals after SCI that kill nearby cells. We aim to improve how macrophages respond to SCI by treating animals with galectin-1 (Gal1), which changes macrophages so they release chemicals that protect, not kill, spinal cord cells. Gal1 could aid cell survival in the spinal cord and improve SCI animals' movement and sensation.
Why use Gal1? Gal1 causes macrophages to release helpful chemicals. Gal1 also benefits other cells after SCI. Gal1 causes spinal cord cells called astrocytes to release chemicals that aid survival/growth of neurons. Gal1 also promotes blood vessel growth.
To discover if Gal1 could benefit humans after SCI, we will use a clinically-relevant rodent SCI model . We expect that Gal1-treated SCI rats will recover walking/sensation better than normal SCI rats. We will also study mice that lack Gal1 (Gal1- mice). Gal1 likely improves repair after SCI, so we expect that Gal1- mice will not recover as well as Gal1+ mice.
To determine how Gal1 improves function after SCI, spinal cord cells will be studied. We expect that Gal1-treated SCI rats will have reduced injury size and more protective macrophages vs normal SCI rats. We expect that Gal1- mice will have larger injury sites and more toxic macrophages vs Gal1+ mice. These results would show that Gal1 protects spinal cord cells after SCI.
Gal1 benefits many different cells, so it could improve recovery significantly. These studies would show that Gal1 aids mobility and sensation after clinically-relevant SCI, and how Gal1 improves function at the cellular level. This work could identify Gal1 as a potential therapy that limits damage after SCI.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ohio, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
214720
Name
Gaudet Andrew D
Region
Ohio
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Improving the immune response to spinal cord injury using galectin-1
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Anatomical Outcomes; Axon Regeneration; Behavioural Outcomes; Cns Disease; Immunology; Macrophages; Neuroimmunology; Neuropathology; Potential Therapy; Spinal Cord Injury
Abstract
The earliest documented cases of spinal cord injury (SCI) are in ancient Egyptian texts. 2500 years later, we are beginning to understand events that prevent repair after SCI. SCI permanently disconnects nerve cells (neurons) from other neurons in the spinal cord. Invading immune cells called macrophages worsen the situation by releasing toxic chemicals after SCI that kill nearby cells. We aim to improve how macrophages respond to SCI by treating animals with galectin-1 (Gal1), which changes macrophages so they release chemicals that protect, not kill, spinal cord cells. Gal1 could aid cell survival in the spinal cord and improve SCI animals' movement and sensation.
Why use Gal1? Gal1 causes macrophages to release helpful chemicals. Gal1 also benefits other cells after SCI. Gal1 causes spinal cord cells called astrocytes to release chemicals that aid survival/growth of neurons. Gal1 also promotes blood vessel growth.
To discover if Gal1 could benefit humans after SCI, we will use a clinically-relevant rodent SCI model . We expect that Gal1-treated SCI rats will recover walking/sensation better than normal SCI rats. We will also study mice that lack Gal1 (Gal1- mice). Gal1 likely improves repair after SCI, so we expect that Gal1- mice will not recover as well as Gal1+ mice.
To determine how Gal1 improves function after SCI, spinal cord cells will be studied. We expect that Gal1-treated SCI rats will have reduced injury size and more protective macrophages vs normal SCI rats. We expect that Gal1- mice will have larger injury sites and more toxic macrophages vs Gal1+ mice. These results would show that Gal1 protects spinal cord cells after SCI.
Gal1 benefits many different cells, so it could improve recovery significantly. These studies would show that Gal1 aids mobility and sensation after clinically-relevant SCI, and how Gal1 improves function at the cellular level. This work could identify Gal1 as a potential therapy that limits damage after SCI.
Competitiondate
201010
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Gaudet, Andrew D
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~